[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 28 of about 28
1. Malandrino P, Al Ghuzlan A, Castaing M, Young J, Caillou B, Travagli JP, Elias D, de Baere T, Dromain C, Paci A, Chanson P, Schlumberger M, Leboulleux S, Baudin E: Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma. Endocr Relat Cancer; 2010 Sep;17(3):797-807
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma.
  • To progress in the stratification of the first-line therapeutic management of metastatic adrenocortical carcinoma (ACC), we searched for prognostic parameters of survival in patients treated with combined mitotane- and cisplatinum-based chemotherapy as first-line.
  • We retrospectively studied prospectively collected parameters from 131 consecutive patients with metastatic ACC (44 with a tissue specimen available) treated at the Gustave Roussy Institute with mitotane- and platinum-based chemotherapy.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenal Cortex Neoplasms / metabolism. Adrenocortical Carcinoma / drug therapy. Adrenocortical Carcinoma / metabolism. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / metabolism

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20592067.001).
  • [ISSN] 1479-6821
  • [Journal-full-title] Endocrine-related cancer
  • [ISO-abbreviation] Endocr. Relat. Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / DNA-Binding Proteins; 78E4J5IB5J / Mitotane; EC 3.1.- / ERCC1 protein, human; EC 3.1.- / Endonucleases; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


2. Schwarte S, Brabant EG, Bastian L, Bruns F: Cortisol as a possible marker of metastatic adrenocortical carcinoma: a case report with 3-year follow-up. Anticancer Res; 2007 Jul-Aug;27(4A):1917-20
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Cortisol as a possible marker of metastatic adrenocortical carcinoma: a case report with 3-year follow-up.
  • BACKGROUND: Adrenocortical carcinoma (ACC) is a rare tumour, sometimes causing glucocorticoid hypersecretion.
  • CASE REPORT: A 55-year-old Caucasian woman presented with adrenal Cushing's disease.
  • Diagnostic work-up revealed hepatic metastatic lesions of an ACC which were treated by right hemihepatectomy.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Biomarkers, Tumor / blood. Diagnostic Errors. Hydrocortisone / blood

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • Hazardous Substances Data Bank. HYDROCORTISONE .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17649795.001).
  • [ISSN] 0250-7005
  • [Journal-full-title] Anticancer research
  • [ISO-abbreviation] Anticancer Res.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Greece
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor; 78E4J5IB5J / Mitotane; WI4X0X7BPJ / Hydrocortisone
  •  go-up   go-down


3. Shen XC, Gu CX, Qiu YQ, Du CJ, Fu YB, Wu JJ: Estrogen receptor expression in adrenocortical carcinoma. J Zhejiang Univ Sci B; 2009 Jan;10(1):1-6
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Estrogen receptor expression in adrenocortical carcinoma.
  • OBJECTIVE: Adrenocortical carcinoma (ACC) is a rare but highly malignant tumor, and its diagnosis is mostly delayed and prognosis is poor.
  • RESULTS: At the time of diagnosis, 4 tumors were classified as Stage I, 4 as Stage II, 3 as Stage III, and 6 as Stage IV.
  • [MeSH-major] Adrenal Cortex Neoplasms / metabolism. Adrenal Cortex Neoplasms / mortality. Adrenocortical Carcinoma / metabolism. Adrenocortical Carcinoma / mortality. Biomarkers, Tumor / analysis. Neoplasm Proteins / analysis. Receptors, Estrogen / analysis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • [Cites] Curr Urol Rep. 2004 Feb;5(1):65-72 [14733841.001]
  • [Cites] J Urol. 1978 Dec;120(6):660-5 [731800.001]
  • [Cites] Cancer Res. 1983 Aug;43(8):3583-5 [6861130.001]
  • [Cites] Am J Surg Pathol. 1984 Mar;8(3):163-9 [6703192.001]
  • [Cites] Endocr Rev. 1987 Feb;8(1):29-43 [3549276.001]
  • [Cites] Cancer Res. 1989 Apr 1;49(7):1882-4 [2924327.001]
  • [Cites] Am J Clin Pathol. 1992 Jan;97(1):73-83 [1728867.001]
  • [Cites] Surgery. 1992 Dec;112(6):963-70; discussion 970-1 [1455321.001]
  • [Cites] Surg Oncol Clin N Am. 1998 Oct;7(4):791-805 [9735134.001]
  • [Cites] World J Urol. 1999 Feb;17(1):26-34 [10096148.001]
  • [Cites] Ann R Coll Surg Engl. 1958 Sep;23(3):155-86 [13571886.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):667-80 [16172199.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • (PMID = 19198016.001).
  • [ISSN] 1673-1581
  • [Journal-full-title] Journal of Zhejiang University. Science. B
  • [ISO-abbreviation] J Zhejiang Univ Sci B
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Neoplasm Proteins; 0 / Receptors, Estrogen
  • [Other-IDs] NLM/ PMC2613956
  •  go-up   go-down


Advertisement
4. Leboulleux S, Deandreis D, Al Ghuzlan A, Aupérin A, Goéré D, Dromain C, Elias D, Caillou B, Travagli JP, De Baere T, Lumbroso J, Young J, Schlumberger M, Baudin E: Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis? Eur J Endocrinol; 2010 Jun;162(6):1147-53
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?
  • CONTEXT: Peritoneal carcinomatosis (PC) is a rare site of distant metastases in patients with adrenocortical cancer (ACC).
  • Patients had stage I disease in 2 cases, stage II disease in 32 cases, stage III disease in 7 cases, stage IV disease in 21 cases, and unknown stage disease in 2 cases.
  • Neither tumor size, stage, functional status, completeness of surgery, nor plasma level of op'DDD was associated with the occurrence of PC.

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20348273.001).
  • [ISSN] 1479-683X
  • [Journal-full-title] European journal of endocrinology
  • [ISO-abbreviation] Eur. J. Endocrinol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  •  go-up   go-down


5. Assié G, Antoni G, Tissier F, Caillou B, Abiven G, Gicquel C, Leboulleux S, Travagli JP, Dromain C, Bertagna X, Bertherat J, Schlumberger M, Baudin E: Prognostic parameters of metastatic adrenocortical carcinoma. J Clin Endocrinol Metab; 2007 Jan;92(1):148-54
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Prognostic parameters of metastatic adrenocortical carcinoma.
  • CONTEXT: Prognostic parameters of metastatic adrenocortical carcinoma (ACC) are poorly characterized.
  • OBJECTIVE: The objective of the study was to describe the clinical presentation of metastatic ACC and determine prognostic factors for survival.
  • PATIENTS: Participants included 124 consecutive patients with metastatic ACC, 70 from Gustave-Roussy Institute (main cohort) and 54 patients from the Cochin Hospital (validation cohort).
  • In univariate analysis, the presence of hepatic and bone metastases, the number of metastatic lesions and the number of tumoral organs at the time of the first metastasis, a high mitotic rate (>20 per 50 high-power field), and atypical mitoses in the primary tumor predicted survival (P = 0.05, 0.003, 0.046, 0.001, 0.01, and < 0.001, respectively).
  • CONCLUSION: Metastatic ACC is a heterogeneous disease with poor outcome.
  • [MeSH-major] Adrenal Cortex Neoplasms / mortality

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17062775.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  •  go-up   go-down


6. Chalasani S, Vats HS, Banerjee TK, McKenzie AK: Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy. Clin Med Res; 2009 Jun;7(1-2):48-51
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic virilizing adrenocortical carcinoma: a rare case of cure with surgery and mitotane therapy.
  • A 57-year-old white woman with metastases to lungs and liver from virilizing adrenocortical carcinoma (ACC) was treated with radical nephroadrenalectomy followed by oral mitotane 3 to 6 g/day for 5 months.
  • Stage I and II disease is curable with surgery.
  • Stage III and IV disease may benefit from mitotane orally with gradual adjustment of the dosage to a tolerable level.
  • An international study has been started by randomizing between two of the above combinations by the Collaborative Group for Adrenocortical Carcinoma Treatment.
  • [MeSH-major] Adrenocortical Carcinoma / diagnosis. Adrenocortical Carcinoma / drug therapy. Adrenocortical Carcinoma / surgery. Antineoplastic Agents, Hormonal / therapeutic use. Mitotane / therapeutic use

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Obstet Gynecol. 1995 Jun;172(6):1912-4; discussion 1914-5 [7778652.001]
  • [Cites] Surgery. 1991 Dec;110(6):1006-13 [1745969.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • [Cites] J Clin Endocrinol Metab. 2000 Jun;85(6):2234-8 [10852456.001]
  • [Cites] Ann Oncol. 2000 Oct;11(10):1281-7 [11106117.001]
  • [Cites] J Endocrinol Invest. 2001 Jul-Aug;24(7):532-5 [11508789.001]
  • [Cites] World J Surg. 2001 Jul;25(7):914-26 [11572033.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1385-92 [11745214.001]
  • [Cites] J Clin Endocrinol Metab. 2002 Oct;87(10):4452-6 [12364417.001]
  • [Cites] J Urol. 2003 Jan;169(1):5-11 [12478091.001]
  • [Cites] Ann Intern Med. 2003 Mar 4;138(5):424-9 [12614096.001]
  • [Cites] Ann Intern Med. 1975 May;82(5):677-9 [1137262.001]
  • [Cites] Eur J Cancer Clin Oncol. 1984 Jan;20(1):47-53 [6537915.001]
  • [Cites] Eur J Surg Oncol. 1990 Dec;16(6):500-6 [2253796.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):657-66 [16172198.001]
  • (PMID = 19574489.001).
  • [ISSN] 1554-6179
  • [Journal-full-title] Clinical medicine & research
  • [ISO-abbreviation] Clin Med Res
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  • [Other-IDs] NLM/ PMC2705271
  •  go-up   go-down


7. Patel VV, Shah DS, Raychaudhari CR, Patel KB: Giant non-functioning adrenocortical carcinoma: A rare childhood tumor. Indian J Med Paediatr Oncol; 2010 Apr;31(2):65-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Giant non-functioning adrenocortical carcinoma: A rare childhood tumor.
  • Adrenocortical carcinoma (ACC) is a rare malignancy, especially in children.
  • With a stage IV disease, the patient died after 2 months from diagnosis.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Radiographics. 1999 Jul-Aug;19(4):989-1008 [10464805.001]
  • [Cites] AJR Am J Roentgenol. 2001 Mar;176(3):755-9 [11222220.001]
  • [Cites] World J Surg. 2001 Jul;25(7):891-7 [11572030.001]
  • [Cites] Pediatr Pathol Mol Med. 2003 Sep-Oct;22(5):405-10 [14692192.001]
  • [Cites] J Clin Oncol. 2004 Mar 1;22(5):838-45 [14990639.001]
  • [Cites] Endocr Relat Cancer. 2005 Sep;12(3):657-66 [16172198.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Jul;82(7):2027-31 [9215267.001]
  • [Cites] Jpn J Clin Oncol. 2007 Feb;37(2):108-13 [17277000.001]
  • [Cites] Neth J Med. 2007 Feb;65(2):55-60 [17379929.001]
  • [Cites] Oncology. 1988;45(1):15-7 [3340389.001]
  • [Cites] Jpn J Surg. 1985 Nov;15(6):477-82 [3831502.001]
  • [Cites] Jpn J Clin Oncol. 2009 Mar;39(3):183-5 [19168875.001]
  • [Cites] J Clin Endocrinol Metab. 2006 Jun;91(6):2027-37 [16551738.001]
  • (PMID = 21209768.001).
  • [ISSN] 0975-2129
  • [Journal-full-title] Indian journal of medical and paediatric oncology : official journal of Indian Society of Medical & Paediatric Oncology
  • [ISO-abbreviation] Indian J Med Paediatr Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC2970938
  • [Keywords] NOTNLM ; Adrenocortical carcinoma / adrenocortical tumor / nonfunctioning
  •  go-up   go-down


8. Nishida S, Itoh N, Sasao T, Masumori N, Taguchi K, Tsukamoto T: Adrenocortical carcinoma: retrospective study of 14 patients experienced at a single institution over 34 years. Int J Urol; 2007 Jul;14(7):581-4
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: retrospective study of 14 patients experienced at a single institution over 34 years.
  • OBJECTIVE: To review clinical outcome of patients with adrenocortical carcinoma experienced at a single institute over 34 years.
  • Two patients were classified as having stage II disease, seven as stage III and five as stage IV.
  • The median survival periods were 2 months in patients with stage IV and 108 months in those with stages II and III (P = 0.136).
  • CONCLUSIONS: Adrenocortical carcinoma is a rare disease but frequently recurs.
  • [MeSH-major] Adrenal Cortex Neoplasms. Adrenocortical Carcinoma

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17645596.001).
  • [ISSN] 0919-8172
  • [Journal-full-title] International journal of urology : official journal of the Japanese Urological Association
  • [ISO-abbreviation] Int. J. Urol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Australia
  •  go-up   go-down


9. Mackie GC, Shulkin BL, Ribeiro RC, Worden FP, Gauger PG, Mody RJ, Connolly LP, Kunter G, Rodriguez-Galindo C, Wallis JW, Hurwitz CA, Schteingart DE: Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma. J Clin Endocrinol Metab; 2006 Jul;91(7):2665-71
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Use of [18F]fluorodeoxyglucose positron emission tomography in evaluating locally recurrent and metastatic adrenocortical carcinoma.
  • CONTEXT: Adrenocortical carcinomas are uncommon, and their evaluation by [(18)F]fluorodeoxyglucose positron emission tomography (FDG PET) has not been well evaluated.
  • OBJECTIVE: The purpose of this study was to examine the potential utility of FDG PET in the detection of recurrent or metastatic adrenocortical carcinoma.
  • DESIGN: In patients with known adrenocortical carcinoma who underwent FDG-PET imaging for suspected recurrence or metastasis, FDG activity was compared with other imaging findings, clinical features, and the presence or absence of disease as confirmed by resection, biopsy, or clinical follow-up.
  • CONCLUSIONS: Most adrenocortical carcinomas accumulate and retain FDG and thus can be visualized by PET.
  • [MeSH-major] Adrenal Cortex Neoplasms / radionuclide imaging. Fluorodeoxyglucose F18. Neoplasm Metastasis / radionuclide imaging. Neoplasm Recurrence, Local / radionuclide imaging. Positron-Emission Tomography

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16621901.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Grant] United States / NCI NIH HHS / CA / 5R25 CA23944; United States / NCI NIH HHS / CA / CA 21765; United States / NCI NIH HHS / CA / CA 54216; United States / NCRR NIH HHS / RR / M01-RR00042
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0Z5B2CJX4D / Fluorodeoxyglucose F18
  •  go-up   go-down


10. Pacella CM, Stasi R, Bizzarri G, Pacella S, Graziano FM, Guglielmi R, Papini E: Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma. Eur J Radiol; 2008 Apr;66(1):88-94
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Percutaneous laser ablation of unresectable primary and metastatic adrenocortical carcinoma.
  • PURPOSE: To evaluate the feasibility, safety, and clinical benefits of percutaneous laser ablation (PLA) in patients with unresectable primary and metastatic adrenocortical carcinoma (ACC).
  • CONCLUSIONS: Percutaneous laser ablation is a feasible, safe and well tolerated procedure for the palliative treatment of unresectable primary and metastatic ACC.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery. Laser Therapy / methods. Liver Neoplasms / surgery

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17498906.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Ireland
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


11. Butler C, Butler WM, Rizvi AA: Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma. Endocr Pract; 2010 May-Jun;16(3):441-5
Hazardous Substances Data Bank. NICOTINAMIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Sustained remission with the kinase inhibitor sorafenib in stage IV metastatic adrenocortical carcinoma.
  • OBJECTIVE: To report our experience using kinase inhibition therapy with sorafenib in a patient with advanced adrenocortical carcinoma.
  • An 8-cm left adrenal lesion was found on computed tomography, removed surgically, and confirmed as adrenal carcinoma on pathologic examination.
  • Postoperative scanning revealed metastases to both lungs and the liver that were confirmed by fine-needle biopsy, thus establishing stage IV disease.
  • A trial of sorafenib resulted in regression and eventual resolution of bilateral metastatic lung lesions, reduction in size of the hepatic lesion, normalization of androgen hypersecretion, and marked clinical improvement.
  • CONCLUSION: Multiple kinase inhibitors such as sorafenib provide targeted oncologic treatment and may be effective in treating advanced adrenal cancer.
  • [MeSH-minor] Adrenocortical Carcinoma / pathology. Adrenocortical Carcinoma / secondary. Female. Humans. Middle Aged. Niacinamide / analogs & derivatives. Phenylurea Compounds

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20061282.001).
  • [ISSN] 1934-2403
  • [Journal-full-title] Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists
  • [ISO-abbreviation] Endocr Pract
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Benzenesulfonates; 0 / Phenylurea Compounds; 0 / Protein Kinase Inhibitors; 0 / Pyridines; 25X51I8RD4 / Niacinamide; 9ZOQ3TZI87 / sorafenib
  •  go-up   go-down


12. Ohwada S, Izumi M, Kawate S, Hamada K, Toya H, Togo N, Horiguchi J, Koibuchi Y, Takahashi T, Yamada M: Surgical outcome of stage III and IV adrenocortical carcinoma. Jpn J Clin Oncol; 2007 Feb;37(2):108-13
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Surgical outcome of stage III and IV adrenocortical carcinoma.
  • BACKGROUND: Adrenocortical carcinoma (ACC) is a rare tumor usually diagnosed at an advanced stage on invasion of or adherence to adjacent organs.
  • We report surgical outcome of stage III and IV ACCs.
  • METHODS: ACCs from seven patients at clinical stage II (n = 1), III (n = 4), or IV (n = 2) were resected.
  • RESULTS: The pathological stage was stage III in five patients and stage IV in two patients.
  • The estimated 3-year disease-free and overall survivals for stage III were 20% and 40%, respectively, with a median follow-up of 32 months (range, 11-58).
  • The 3-year disease-free and overall survivals for stage III and IV were 14.3% and 28.6%, respectively.
  • CONCLUSIONS: Resection for stage III, IV ACCs affords the possibility of negative margins, acceptable peri-operative morbidity and mortality, and prolongs survival in selected patients.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17277000.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  •  go-up   go-down


13. Tucci S Jr, Martins AC, Suaid HJ, Cologna AJ, Reis RB: The impact of tumor stage on prognosis in children with adrenocortical carcinoma. J Urol; 2005 Dec;174(6):2338-42, discussion 2342
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] The impact of tumor stage on prognosis in children with adrenocortical carcinoma.
  • PURPOSE: We evaluated treatment outcomes in children with adrenocortical carcinoma.
  • Children with incomplete excision of the tumor and/or stage IV disease received adjuvant chemotherapy.
  • Patient age, tumor stage or size and vascular invasion were associated with survival in univariate analysis.
  • Tumor stage was the only independent factor associated with survival in multivariate analysis.
  • The overall 5-year survival rates according to tumor stage were 100% in stage I, 85% in stage II, 40% in stage III and 0% in stage IV.
  • A total of 10 children with stage IV disease treated with chemotherapy died within a median of 6 months.
  • CONCLUSIONS: Tumor stage was the most relevant prognostic factor for children with adrenocortical carcinoma.
  • [MeSH-major] Adrenal Cortex Neoplasms / diagnosis. Adrenocortical Carcinoma / diagnosis

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16280838.001).
  • [ISSN] 0022-5347
  • [Journal-full-title] The Journal of urology
  • [ISO-abbreviation] J. Urol.
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


14. Fassnacht M, Wittekind C, Allolio B: [Current TNM classification systems for adrenocortical carcinoma]. Pathologe; 2010 Sep;31(5):374-8
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Current TNM classification systems for adrenocortical carcinoma].
  • Adrenocortical carcinoma (ACC) is a rare malignancy and often difficult to diagnose.
  • However, an analysis based on data from the German ACC Registry revealed several shortcomings of this classification; in particular, the outcome of patients with UICC stage II and III was not significantly different.
  • Therefore, the European Network for the Study of Adrenal Tumours (ENSAT) developed a revised staging system, the superiority of which was recently confirmed in an independent American cohort.
  • In the ENSAT classification, stage I (tumors ≤ 5 cm) and II (tumors < 5 cm) are non-infiltrating tumors without positive lymph nodes and distant metastases.
  • Stage III is defined by the presence of positive lymph nodes, infiltration of surrounding tissue, or venous tumor thrombus.
  • Stage IV is restricted to patients with distant metastasis.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Neoplasm Staging / methods
  • [MeSH-minor] Adrenal Cortex / pathology. Cohort Studies. Disease Progression. Humans. Lymphatic Metastasis / pathology. Neoplasm Invasiveness / pathology. Neoplastic Cells, Circulating. Prognosis. Registries

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20703482.001).
  • [ISSN] 1432-1963
  • [Journal-full-title] Der Pathologe
  • [ISO-abbreviation] Pathologe
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


15. Turbendian HK, Strong VE, Hsu M, Ghossein RA, Fahey TJ 3rd: Adrenocortical carcinoma: the influence of large vessel extension. Surgery; 2010 Dec;148(6):1057-64; discussion 1064
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: the influence of large vessel extension.
  • BACKGROUND: The impact of large vessel extension (LVE) as a prognostic factor for adrenocortical carcinoma (ACC) is not fully understood.
  • RESULTS: Multivariable regression analysis showed a significant association for decreased survival with Stage III and IV disease and LVE.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Renal Veins / pathology. Vena Cava, Inferior / pathology

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright © 2010 Mosby, Inc. All rights reserved.
  • (PMID = 21134533.001).
  • [ISSN] 1532-7361
  • [Journal-full-title] Surgery
  • [ISO-abbreviation] Surgery
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


16. Hanna AM, Pham TH, Askegard-Giesmann JR, Grams JM, Iqbal CW, Stavlo P, Moir CR: Outcome of adrenocortical tumors in children. J Pediatr Surg; 2008 May;43(5):843-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Outcome of adrenocortical tumors in children.
  • PURPOSE: This study reviews adrenocortical tumors in children to determine factors that significantly affect outcome.
  • METHODS: An institutional review board-approved retrospective review from 1976 to 2005 identified 23 patients younger than 19 years old with histologic confirmation of adrenocortical carcinoma (ACC) and adenomas.
  • RESULTS: The mean age of the 23 children was 9.0 +/- 1.6 years; girls predominated (female-to-male ratio = 1.9:1) as did cancers (ACC 16, adenoma 7); tumor hormone production (74%); and advanced stage for disease (66%).
  • For ACC stage III and IV, median survival was 21 months, 5-year survival was 0%.
  • [MeSH-major] Adenoma / mortality. Adenoma / surgery. Adrenal Cortex Neoplasms / mortality. Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / mortality. Adrenocortical Carcinoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18485950.001).
  • [ISSN] 1531-5037
  • [Journal-full-title] Journal of pediatric surgery
  • [ISO-abbreviation] J. Pediatr. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


17. Gomez-Rivera F, Medina-Franco H, Arch-Ferrer JE, Heslin MJ: Adrenocortical carcinoma: a single institution experience. Am Surg; 2005 Jan;71(1):90-4
Genetic Alliance. consumer health - Adrenocortical Carcinoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adrenocortical carcinoma: a single institution experience.
  • Adrenocortical carcinoma (ADCC) ranks among the least common malignant endocrine tumors.
  • Seven patients presented with stage II, five with stage III, four with stage IV, and in one could not be determined.
  • Median follow-up was 12.8 months, median survival 67, 13, and 3 months for stages II, III, and IV, respectively.
  • Older age, distant metastasis, nonoperative management, positive margins, advanced tumor stage, and venous invasion were significantly associated with worse overall actuarial survival.
  • Factors associated with a worse prognosis were stage of disease, nonoperative management, positive surgical margins, vascular invasion, and older age.
  • [MeSH-major] Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15757066.001).
  • [ISSN] 0003-1348
  • [Journal-full-title] The American surgeon
  • [ISO-abbreviation] Am Surg
  • [Language] eng
  • [Publication-type] Comparative Study; Journal Article
  • [Publication-country] United States
  •  go-up   go-down


18. Ohwada S, Izumi M, Tanahashi Y, Kawate S, Hamada K, Tsutsumi H, Horiguchi J, Koibuchi Y, Takahashi T, Yamada M: Combined liver and inferior vena cava resection for adrenocortical carcinoma. Surg Today; 2007;37(4):291-7
Hazardous Substances Data Bank. TEFLON .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Combined liver and inferior vena cava resection for adrenocortical carcinoma.
  • PURPOSE: Adrenocortical carcinoma (ACC) is a rare malignancy, usually diagnosed at an advanced stage when it has invaded or adhered to adjacent organs.
  • METHODS: Six patients with clinical stage III (n = 4) or IV (n = 2) ACC underwent combined resection of the liver and IVC.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / secondary. Adrenocortical Carcinoma / surgery. Liver Neoplasms / secondary. Liver Neoplasms / surgery. Vena Cava, Inferior / surgery

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17387560.001).
  • [ISSN] 0941-1291
  • [Journal-full-title] Surgery today
  • [ISO-abbreviation] Surg. Today
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Japan
  • [Chemical-registry-number] 9002-84-0 / Polytetrafluoroethylene
  •  go-up   go-down


19. Fassnacht M, Hahner S, Polat B, Koschker AC, Kenn W, Flentje M, Allolio B: Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma. J Clin Endocrinol Metab; 2006 Nov;91(11):4501-4
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma.
  • CONTEXT: Local tumor recurrence is common in adrenocortical carcinoma (ACC) and is the most frequent cause for reoperation.
  • Fourteen patients without distant metastases (World Health Organization stage I, one patient; stage II, seven; stage III, three; and stage IV, three) were matched with 14 patients for resection status, adjuvant mitotane treatment, stage, and tumor size.
  • [MeSH-major] Adrenal Cortex Neoplasms / radiotherapy. Adrenal Cortex Neoplasms / surgery. Adrenocortical Carcinoma / radiotherapy. Adrenocortical Carcinoma / surgery. Neoplasm Recurrence, Local / radiotherapy

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] J Clin Endocrinol Metab. 2006 Nov;91(11):4250-2 [17088440.001]
  • (PMID = 16895957.001).
  • [ISSN] 0021-972X
  • [Journal-full-title] The Journal of clinical endocrinology and metabolism
  • [ISO-abbreviation] J. Clin. Endocrinol. Metab.
  • [Language] eng
  • [Publication-type] Comparative Study; Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents, Hormonal; 78E4J5IB5J / Mitotane
  •  go-up   go-down


20. Volante M, Bollito E, Sperone P, Tavaglione V, Daffara F, Porpiglia F, Terzolo M, Berruti A, Papotti M: Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification. Histopathology; 2009 Nov;55(5):535-43
University of Turin Instituional Repository AperTO. Full Text from .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological study of a series of 92 adrenocortical carcinomas: from a proposal of simplified diagnostic algorithm to prognostic stratification.
  • AIMS: Pathological diagnosis of adrenocortical carcinoma relies on several microscopic features commonly used in combination in different scoring systems that are sometimes subjective and/or time consuming.
  • The aim was to investigate the impact of individual pathological parameters in the diagnosis and prognosis of adrenocortical carcinoma.
  • The presence of disruption of the reticular network, as highlighted by histochemical staining, was present in all adrenocortical carcinomas and the inclusion of at least one of the three following additional parameters - mitotic index >5/50 high-power fields (HPF), presence of necrosis and presence of vascular invasion - gave an algorithm with 100% sensitivity and specificity to recognize malignant tumours according to the Weiss system, with easier and more practical applicability.
  • Moreover, on multivariate analysis, stage III/IV and mitotic count >9/50 HPF showed a strong adverse impact on disease-free and overall survival, leading to the identification of three risk groups affected by a significantly different prognosis.
  • CONCLUSIONS: We have defined an easy-to-perform and highly specific and sensitive algorithm for the diagnosis and prognostic categorization of adrenocortical tumours.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology. Algorithms

  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19912359.001).
  • [ISSN] 1365-2559
  • [Journal-full-title] Histopathology
  • [ISO-abbreviation] Histopathology
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  •  go-up   go-down


21. Fassnacht M, Johanssen S, Quinkler M, Bucsky P, Willenberg HS, Beuschlein F, Terzolo M, Mueller HH, Hahner S, Allolio B, German Adrenocortical Carcinoma Registry Group, European Network for the Study of Adrenal Tumors: Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer; 2009 Jan 15;115(2):243-50
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Limited prognostic value of the 2004 International Union Against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification.
  • BACKGROUND: Adrenocortical carcinoma (ACC) is a rare malignancy, and it was only in 2004 that the International Union Against Cancer (UICC) defined TNM criteria and published the first staging classification.
  • Patients were assigned to UICC tumor stage, and disease-specific survival (DSS) was assessed.
  • RESULTS: In total, 416 patients with a mean follow-up of 36 months met the inclusion criteria (stage I, n=23 patients; stage II, n=176 patients; stage III, n=67 patients; stage IV, n=150 patients).
  • Kaplan-Meier analysis revealed a stage-dependent DSS.
  • However, DSS in patients with stage II ACC did not differ significantly from DSS in patients with stage III ACC (hazard ratio, 1.38; 95% confidence interval, 0.89-2.16).
  • Furthermore, patients who had stage IV ACC without distant metastases had an improved DSS compared with patients who had metastatic disease (P=.004).
  • An analysis of different potential risk factors for defining stage III ACC revealed important roles in DSS for tumor infiltration in surrounding tissue, venous tumor thrombus (VTT), and positive lymph nodes; whereas tumor invasion in adjacent organs carried a prognosis similar to that of infiltration in surrounding tissue only.
  • On the basis of the current analysis, a revised classification with superior prognostic accuracy is proposed (the European Network for the Study of Adrenal Tumors classification).
  • In this system, stage III ACC is defined by the presence of positive lymph nodes, infiltration of surrounding tissue, or VTT; and stage IV ACC is restricted to patients with distant metastasis.
  • [MeSH-major] Adrenocortical Carcinoma / pathology. Neoplasm Staging / classification

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright (c) 2009 American Cancer Society.
  • [CommentIn] Cancer. 2009 Dec 15;115(24):5847; author reply 5848 [19827149.001]
  • (PMID = 19025987.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Evaluation Studies; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Investigator] Allolio B; Behrend M; Bucsky P; Brauckhoff M; Fasanacht M; Fottner C; Haaf M; Hahner S; Johanssen S; Koschker AC; Langer P; Laubner K; Linden T; Maeder U; Morcos M; Oelkers W; Quinkler M; Reincke M; Reisch N; Saeger W; Weismann D; Willenberg HS; Wortmann S; Baudin E; Bertherat J; Beuschlein F; Mannelli M; Terzolo M
  •  go-up   go-down


22. Gross MD, Avram A, Fig LM, Fanti S, Al-Nahhas A, Rubello D: PET in the diagnostic evaluation of adrenal tumors. Q J Nucl Med Mol Imaging; 2007 Sep;51(3):272-83
MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] PET in the diagnostic evaluation of adrenal tumors.
  • Early experience with positron emission tomography (PET) has provided exciting results in the evaluation of a broad spectrum of neoplasms, to include primary adrenal tumors, their metastases and metastatic disease to the adrenal glands.
  • By virtue of the well-recognized propensity of malignancies to preferentially use glycolysis as an important energy source and the stimulation of mechanisms designed to absorb substrate glucose, the glucose analog, [18F]fluorodeoxyglucose, has become a successful radiopharmaceutical in the scintigraphic evaluation of adrenal tumors.
  • Building upon prior experience gained with imaging the adrenal gland, other positron-labeled radiopharmaceuticals are finding their way into clinical use.
  • The 11b-hydroxylase inhibitor, metomidate labeled with 11C has been used to scintigraphically identify tissues of adrenocortical origin, to accurately identify recurrent and metastatic adrenocortical carcinoma and may be useful in assessing the malignant potential of these tumors and predicting survival in afflicted patients.
  • Additional structural and functional information provided by computed tomography (CT), performed as part of hybrid PET/CT imaging directly complements PET and adds measurable diagnostic value in the evaluation of adrenal tumors.
  • [MeSH-major] Adrenal Gland Neoplasms / radionuclide imaging. Adrenal Glands / radionuclide imaging. Image Enhancement / methods. Molecular Probe Techniques. Positron-Emission Tomography / methods

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17464268.001).
  • [ISSN] 1824-4785
  • [Journal-full-title] The quarterly journal of nuclear medicine and molecular imaging : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology (IAR), [and] Section of the Society of Radiopharmaceutical Chemistry and Biology
  • [ISO-abbreviation] Q J Nucl Med Mol Imaging
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Italy
  • [Number-of-references] 57
  •  go-up   go-down


23. Garg K, Lee P, Ro JY, Qu Z, Troncoso P, Ayala AG: Adenomatoid tumor of the adrenal gland: a clinicopathologic study of 3 cases. Ann Diagn Pathol; 2005 Feb;9(1):11-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Adenomatoid tumor of the adrenal gland: a clinicopathologic study of 3 cases.
  • Rare extragenital adenomatoid tumors have been identified in the adrenal glands, heart, mesentery, pleura, and lymph nodes.
  • In the adrenal gland, adenomatoid tumors may pose a diagnostic challenge.
  • The differential diagnosis includes adrenocortical carcinoma and metastatic carcinoma, especially signet ring cell carcinoma.
  • We present 3 cases of adrenal adenomatoid tumors, including one with a concurrent large hemorrhagic vascular adrenal cyst.
  • One patient presented with abdominal pain due to the presence of a concurrent large adrenal cyst.
  • In our experience, the key to the diagnosis of this rare benign tumor is to consider adenomatoid tumor in the differential diagnosis of any glandular tumor occurring in the adrenal gland.
  • [MeSH-major] Adenoma / pathology. Adrenal Gland Neoplasms / pathology
  • [MeSH-minor] Adenocarcinoma / diagnosis. Adult. Biomarkers, Tumor / metabolism. Calbindin 2. Carcinoma, Signet Ring Cell / diagnosis. Carcinoma, Signet Ring Cell / secondary. Cysts / complications. Cysts / metabolism. Cysts / pathology. Diagnosis, Differential. Humans. Immunohistochemistry. Keratins / metabolism. Male. Middle Aged. S100 Calcium Binding Protein G / metabolism. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15692945.001).
  • [ISSN] 1092-9134
  • [Journal-full-title] Annals of diagnostic pathology
  • [ISO-abbreviation] Ann Diagn Pathol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / CALB2 protein, human; 0 / Calbindin 2; 0 / S100 Calcium Binding Protein G; 68238-35-7 / Keratins
  •  go-up   go-down


24. Soga H, Takenaka A, Ooba T, Nakano Y, Miyake H, Takeda M, Tanaka K, Hara I, Fujisawa M: A twelve-year experience with adrenal cortical carcinoma in a single institution: long-term survival after surgical treatment and transcatheter arterial embolization. Urol Int; 2009;82(2):222-6

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A twelve-year experience with adrenal cortical carcinoma in a single institution: long-term survival after surgical treatment and transcatheter arterial embolization.
  • INTRODUCTION: We retrospectively analyzed 6 cases of adrenal cortical carcinoma (ACC) treated during a 12-year period at a single institution.
  • Three patients were clinically classified as stage II, 2 as stage III and 1 as stage IV with bone metastasis.
  • [MeSH-major] Adrenal Cortex Neoplasms / therapy. Adrenalectomy. Adrenocortical Carcinoma / therapy. Chemoembolization, Therapeutic

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2009 S. Karger AG, Basel.
  • (PMID = 19322014.001).
  • [ISSN] 1423-0399
  • [Journal-full-title] Urologia internationalis
  • [ISO-abbreviation] Urol. Int.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


25. Sasano H, Suzuki T, Moriya T: Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma. Endocr Pathol; 2006;17(4):345-54
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Recent advances in histopathology and immunohistochemistry of adrenocortical carcinoma.
  • Discerning malignancy in resected adrenocortical neoplasms can pose diagnostic difficulty.
  • Histological scoring systems evaluating multiple parameters, especially the criteria of Weiss, have been shown to be reliable in differential diagnosis between adrenocortical adenoma and carcinoma.
  • A tumor is defined as adrenocortical carcinoma when three or more of the following criteria are met;.
  • The criteria are relatively straightforward and considered the most effective standard for diagnosis of adrenocortical malignancy.
  • However, great care should be taken in applying the criteria to histological evaluation of two relatively rare and peculiar adrenocortical tumors, adrenocortical oncocytoma and pediatric adrenocortical neoplasms.
  • At this juncture, ancillary biological or molecular markers are of little practical value in terms of differential diagnosis between adrenocortical adenoma and carcinoma but tumors with MIB1 or Ki-67 labeling index more than 2.5 may be considered malignant.
  • Prognostic markers of adrenocortical carcinoma have not been established other than complete respectability of the tumor.
  • It sometimes is important for surgical pathologists to differentiate adrenocortical carcinoma from metastatic malignancies of other sites.
  • An immunohistochemical evaluation of adrenal 4 binding protein (Ad4BP) or SF-1, a transcription factor of all steroidogenesis, can aid in this differential diagnosis because nuclear immunoreactivity for this transcription factor is relatively specific to steroid producing cells.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenocortical Carcinoma / pathology
  • [MeSH-minor] Adrenocortical Adenoma / diagnosis. Biomarkers, Tumor / analysis. Cell Count. Cell Nucleus / pathology. Diagnosis, Differential. Humans. Immunohistochemistry / methods. Ki-67 Antigen / analysis. Mitotic Index. Ubiquitin-Protein Ligases / analysis

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • COS Scholar Universe. author profiles.
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17525483.001).
  • [ISSN] 1046-3976
  • [Journal-full-title] Endocrine pathology
  • [ISO-abbreviation] Endocr. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Ki-67 Antigen; EC 6.3.2.19 / MIB1 ligase, human; EC 6.3.2.19 / Ubiquitin-Protein Ligases
  • [Number-of-references] 33
  •  go-up   go-down


26. Yasumoto T, Hayashi S, Shimizu J, Dono K, Nakata S, Sato M, Kitada M, Shimano T: [Radiofrequency ablation combined with transcatheter arterial chemoembolization for the local recurrent tumor after resection of the adrenal metastasis from hepatocellular carcinoma--a case report]. Gan To Kagaku Ryoho; 2009 Nov;36(12):2371-3
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Radiofrequency ablation combined with transcatheter arterial chemoembolization for the local recurrent tumor after resection of the adrenal metastasis from hepatocellular carcinoma--a case report].
  • We report a case of local recurrent tumor after a resection of right adrenal metastasis from hepatocellular carcinoma successfully treated with radiofrequency ablation combined with transcatheter arterial chemoembolization.
  • The lesions were judged to be T4, N0, M0 and Stage IV,then, he was treated as an outpatient on a regular schedule.
  • In July 2003, a right adrenal tumor 2 cm in diameter was detected by computed tomography (CT), but the value of the adrenocortical hormones were normal on blood examination, and he was observed at regular intervals.
  • In February 2005, the adrenal lesion enlarged to 5 cm in diameter and the value of PIVKA-II became high on blood examination, so April 2005, a surgical resection was performed, and it was diagnosed as the metastasis from HCC.
  • It was considered inoperable because of the past operation, and transcatheter arterial chemoembolization of an inferior adrenal artery and a fine branch through a right sub-phrenic artery was performed for the recurrent tumor, and one week after the embolization, radiofrequency ablation was treated by CT fluoroscopy guidance.
  • Transcatheter arterial embolization combined with radiofrequency ablation is considered as a feasible and effective method for not only HCC but also for a local recurrent tumor after resection of the adrenal metastasis from hepatocellular carcinoma.
  • [MeSH-major] Adrenal Gland Neoplasms / secondary. Adrenal Gland Neoplasms / surgery. Carcinoma, Hepatocellular / therapy. Catheter Ablation. Chemoembolization, Therapeutic. Liver Neoplasms / therapy. Neoplasm Recurrence, Local

  • MedlinePlus Health Information. consumer health - Adrenal Gland Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20037426.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  •  go-up   go-down


27. Lee JO, Lee KW, Kim CJ, Kim YJ, Lee HE, Kim H, Kim JH, Bang SM, Kim JS, Lee JS: Metastatic adrenocortical carcinoma treated with sunitinib: a case report. Jpn J Clin Oncol; 2009 Mar;39(3):183-5
Hazardous Substances Data Bank. MITOTANE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Metastatic adrenocortical carcinoma treated with sunitinib: a case report.
  • Adrenocortical carcinoma (ACC) is a rare malignancy with poor prognosis.
  • Palliative chemotherapy can be considered in patients with metastatic disease.
  • To our knowledge, this is the first reported case showing the effects of sunitinib on metastatic ACC.
  • [MeSH-major] Adrenal Cortex Neoplasms / drug therapy. Adrenal Cortex Neoplasms / pathology. Antineoplastic Agents / therapeutic use. Carcinoma / drug therapy. Carcinoma / secondary. Indoles / therapeutic use. Pyrroles / therapeutic use

  • Genetic Alliance. consumer health - Adrenocortical Carcinoma.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19168875.001).
  • [ISSN] 1465-3621
  • [Journal-full-title] Japanese journal of clinical oncology
  • [ISO-abbreviation] Jpn. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inhibitors; 0 / Antineoplastic Agents; 0 / Indoles; 0 / Pyrroles; 0 / sunitinib; 78E4J5IB5J / Mitotane
  •  go-up   go-down


28. Xiao ZJ, Li CL: [Combined therapy of advanced adrenal cortical adenocarcinoma]. Zhonghua Yi Xue Za Zhi; 2010 Aug 10;90(30):2123-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Combined therapy of advanced adrenal cortical adenocarcinoma].
  • OBJECTIVE: To analyze the clinical efficacy of combined therapy in the treatment of advanced adrenal cortical adenocarcinoma.
  • METHODS: The clinical data of 12 cases with advanced adrenal cortical adenocarcinoma at our hospital from 1986 - 2006 were analyzed.
  • Pathological diagnosis was all of adrenal cortical adenocarcinoma.
  • According to the staging criteria of Jacques and Brennan, all 12 cases were of IV stage.
  • CONCLUSION: Combined therapy of adrenal cortical adenocarcinoma is effective to prolong the patient lifespan.
  • [MeSH-major] Adrenal Cortex Neoplasms / pathology. Adrenal Cortex Neoplasms / therapy. Adrenocortical Carcinoma / pathology. Adrenocortical Carcinoma / therapy

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 21029628.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down






Advertisement